This study is testing a new medication called ORKA-001 for adults with moderate-to-severe plaque psoriasis. Researchers want to find the best dose of ORKA-001 and see how safe and effective it is compared to a placebo (an inactive substance). You might be able to join if you are at least 18 years old, have had plaque psoriasis for over 6 months, and your psoriasis covers at least 10% of your body, with a PASI score (Psoriasis Area and Severity Index) of 12 or higher, and an IGA score (Investigator's Global Assessment) of 3 or higher. The main goal is to see how many participants achieve a 100% reduction in their PASI score after 16 weeks. The study is currently recruiting about 160 participants, but its status is unclear.

Study design

This is a randomized, double-blinded, placebo-controlled study involving about 160 participants. It aims to find the best dose of ORKA-001 for plaque psoriasis.

What's involved

The study involves a screening period of up to 6 weeks, an induction period of up to 28 weeks, and a maintenance period of up to 72 weeks. You will receive ORKA-001 or a placebo by subcutaneous (under the skin) injection.

Compensation

Not stated in the trial record.

Follow-up

Participants who do not enter an open-label extension study will be followed for 48 weeks after their last treatment or early withdrawal.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.